CN110092793B - 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用 - Google Patents

山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用 Download PDF

Info

Publication number
CN110092793B
CN110092793B CN201910150938.4A CN201910150938A CN110092793B CN 110092793 B CN110092793 B CN 110092793B CN 201910150938 A CN201910150938 A CN 201910150938A CN 110092793 B CN110092793 B CN 110092793B
Authority
CN
China
Prior art keywords
isoxazole
nmr
cdcl
derivative
oxoindole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910150938.4A
Other languages
English (en)
Other versions
CN110092793A (zh
Inventor
刘雄利
韦启迪
左雄
陈爽
周英
袁伟成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201910150938.4A priority Critical patent/CN110092793B/zh
Publication of CN110092793A publication Critical patent/CN110092793A/zh
Application granted granted Critical
Publication of CN110092793B publication Critical patent/CN110092793B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物，本发明以以各种取代的双功能氧化吲哚‑色酮合成子1、各种取代的(E)‑硝基异恶唑烯烃化合物2在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物3，该类化合物包含潜在的生物活性山酮素骨架、异噁唑骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。且该类骨架化合物对人白血病细胞(K562)具有肿瘤生长抑制活性作用。

Description

山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法 及应用
技术领域
本发明涉及化学技术和药学技术领域，尤其是一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用。
背景技术
根据药物设计的活性骨架拼接和迁越原理，把两个或多个具有生物活性骨架拼接成一个潜在生物活性的多骨架分子在有机化学和医药化学中是极其重要的研究领域。(1)螺六元碳环氧化吲哚广泛存在天然产物和合成药物分子中，吸引了许多化学工作者及医药化学团队的广泛关注，例如，天然产物或活性小分子螺六元碳环氧化吲哚Satavaptan和progesterone receptor agonist II表现明显的生物活性。(2)山酮素骨架也普遍存在天然产物和药物分子中。例如:天然产物分子Ergochrome DD，Diversonol，Desoxydiversonol，Applanatin B和Isocochlioquinone A共享一个山酮素分子单元，这些化合物在解除病痛、经济发展中起着重大作用。(3)异恶唑基团也普遍存在天然产物和药物分子中。例如:异噁唑基团也普遍存在天然产物和药物分子中。如:许多天然产物和药物(Cloxacillin V,muscimol VI,Isoxicam VII,leflunomide VIII,等)。鉴于螺六元碳环氧化吲哚骨架、异噁唑骨架和山酮素骨架具有潜在的生物活性。因此，把螺六元碳环氧化吲哚骨架和异噁唑骨架拼接到山酮素骨架，合成一系列新的潜在多活性官能团的山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值(如图8所示)。
发明内容
本发明的目的是：提供一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法与应用，它是一类重要的医药中间体类似物和药物分子类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明还发现该类化合物在制备防治肿瘤疾病药物中的应用。
本发明是这样实现的：一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物，该化合物具有如下通式(Ⅰ)的结构：
Figure BDA0001981459470000021
式中，R1为甲氧基或氟或氢；R2为甲基或氟或氢；R3为甲基取代的苯基或卤素取代的苯基或苯基或环丙基。
山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物的制备方法，将各种取代的双功能氧化吲哚-色酮合成子1、各种取代的(E)-硝基异恶唑烯烃化合物2在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物3。
合成路线举例如下：
Figure BDA0001981459470000022
其中合成路线中的化合物，其取代基满足R1为甲氧基或氟或氢；R2为甲基或氟或氢；R3为甲基取代的苯基或卤素取代的苯基或苯基或环丙基。
反应机理如下：
Figure BDA0001981459470000023
所述的有机溶剂为乙腈、甲苯、二氯甲烷、或氯仿。
所述的有机小分子碱性催化剂为手性双功能金鸡纳碱衍生的硫脲或芳酰胺、环己基二胺衍生的硫脲或芳酰胺、1,2-二苯基二胺衍生的的硫脲或芳酰胺、等。
有机小分子碱性催化剂举例如下(但需强调的是本发明的有机小分子碱性催化剂不限于如下表示的内容)：
Figure BDA0001981459470000031
各种取代的双功能氧化吲哚-色酮合成子、各种取代的(E)-硝基异恶唑烯烃化合物在有机溶剂中的反应温度为-10℃至40℃，反应时间为1至7天。
山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物在制备防治肿瘤疾病药物中的应用。
通过采用上述技术方案，以各种取代的双功能氧化吲哚-色酮合成子1、各种取代的(E)-硝基异恶唑烯烃化合物2在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物3，该类化合物包含潜在的生物活性山酮素骨架、异噁唑骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。且该骨架化合物对人白血病细胞(K562)具有抑制活性的作用。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图说明
图1及图2为本发明的实施例的化合物3a谱图数据；
图3为化合物3a液相谱图数据；
图4及图5为本发明的实施例的化合物3b谱图数据；
图6为化合物3b液相谱图数据；
图7为本发明的实施例的化合物de-Bc 3e单晶图；
图8为本发明所合成的化合物的设计思路及其创造性。
具体实施方式
本发明的实施例：在反应管中依次加入39.1mg双功能氧化吲哚-色酮合成子1a(0.10mmol)，27.6mg(E)-硝基异恶唑烯烃化合物2a(0.12mmol)，8.9mg奎宁定衍生的的硫脲催化剂C8(15mol％，0.015mmol)和0.5mL新蒸馏的二氯甲烷溶液，室温中搅拌反应5天，TLC检测基本反应完全，直接上样经柱层析(洗脱剂：V(石油醚)：V(乙酸乙酯)＝4:1)纯化得56.5mg化合物3a，白色固体，熔点：174.2-175.8℃；产率91％；97％ee,>20:1dr,[α]D 20＝70.8(c 1.7,MeOH)；The ee was determined by HPLC analysis using a Chiralpak IAcolumn(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.56min；τminor＝45.42min)。核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.59(s,9H),2.12-2.17(m,1H),2.41(s,3H),2.71-2.75(m,1H),3.65-3.68(m,1H),4.14-4.20(m,1H),4.82-4.84(m,1H),5.83-5.85(m,1H),6.83(d,J＝8.0Hz,1H),6.91-6.93(m,2H),6.97-7.00(m,1H),7.04-7.07(m,1H),7.18-7.21(m,2H),7.35-7.37(m,1H),7.45-7.49(m,2H),7.87-7.89(m,1H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.7,31.7,43.4,51.2,80.2,84.6,114.9,118.0,120.6,122.1,122.3,124.6,127.1,128.1,128.9,129.5,134.1,136.2,138.8,148.5,155.6,160.3,171.8,176.4,192.2；HRMS(ESI-TOF)m/z:Calcd.forC35H31N3NaO8[M+Na]+:644.2009；Found:644.2012.
化合物3b至3x的制备方法同化合物3a，投料比与化合物3a相同，可得到化合物3b至3x，反应产率和dr值,ee值见表1和表2，但需强调的是本发明的化合物不限于表1和表2所表示的内容。
表1为一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物的制备方法的化学结构
Figure BDA0001981459470000041
表2为一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物的制备方法的化学结构
Figure BDA0001981459470000051
本实施例制备化合物3b:白色固体,熔点：168.3-170.2℃；产率90％；96％ee,>20:1dr,[α]D 20＝100.1(c 1.8,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝9.06min；τminor＝26.5min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.59(s,9H),2.09(s,3H),2.12-2.15(m,1H),2.41(s,3H),2.69-2.73(m,1H),3.63-3.66(m,1H),4.12-4.17(m,1H),4.79-4.81(m,1H),5.80-5.82(m,1H),6.70-6.72(m,3H),6.82(d,J＝8.5Hz,1H),7.03-7.06(m,1H),7.18-7.20(m,2H),7.33-7.35(m,1H),7.43-7.47(m,1H),7.49-7.51(m,1H),7.86-7.88(m,1H)；13C NMR(CDCl3,125MHz)δ:11.7,20.9,28.0,29.7,31.7,43.4,51.2,80.2,84.4,114.9,117.9,120.5,122.0,122.2,124.5,127.0,128.7,128.8,129.7,131.0,136.1,137.6,138.8,148.5,155.5,160.2,171.9,176.4,192.2；HRMS(ESI-TOF)m/z:Calcd.for C36H33N3NaO8[M+Na]+:658.2165；Found:658.2168.
本实施例制备化合物3c:白色固体,熔点：190.5-192.2℃；产率88％；90％ee,>20:1dr,[α]D 20＝54.0(c 2.0,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝9.44min；τminor＝35.61min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),1.97(s,3H),2.04-2.09(m,1H),2.33(s,3H),2.63-2.67(m,1H),3.54-3.56(m,1H),4.08-4.12(m,1H),4.75-4.77(m,1H),5.73-5.75(m,1H),6.70-6.76(m,4H),6.95-6.99(m,1H),7.10-7.12(m,2H),7.26-7.28(m,1H),7.36-7.42(m,2H),7.80(d,J＝6.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:11.6,21.1,28.1,29.7,31.6,43.4,51.2,80.4,84.5,114.8,117.9,120.6,122.2,122.3,124.5,127.0,127.8,128.7,129.6,133.9,136.1,138.8,148.6,155.5,160.3,171.8,176.3,192.3；HRMS(ESI-TOF)m/z:Calcd.forC36H33N3NaO8[M+Na]+:658.2160；Found:658.2165.
本实施例制备化合物3d:白色固体,熔点：174.2-176.2℃；产率85％；94％ee,>20:1dr,[α]D 20＝39.8(c 3.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.01min；τminor＝42.96min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.63(s,9H),1.96(s,3H),2.17-2.23(m,1H),2.39(s,3H),2.69-2.73(m,1H),4.00-4.04(m,1H),4.22-4.29(m,1H),4.85-4.89(m,1H),5.78-5.82(m,1H),6.68(d,J＝8.5Hz,1H),6.82(d,J＝8.5Hz,1H),6.86-6.89(m,1H),6.91-6.94(m,1H),7.04-7.07(m,1H),7.12-7.19(m,2H),7.38(d,J＝7.0Hz,1H),7.41-7.48(m,2H),7.50(d,J＝7.5Hz,1H),7.87-7.89(m,1H)；13C NMR(CDCl3,125MHz)δ:11.7,19.6,28.1,29.7,31.9,43.5,51.1,80.6,84.6,114.8,117.9,120.6,122.0,122.6,124.0,126.0,126.3,127.0,127.9,129.0,129.1,130.5,133.0,136.1,138.8,148.6,155.6,160.3,171.9,177.1,192.4；HRMS(ESI-TOF)m/z:Calcd.for C36H33N3NaO8[M+Na]+:658.2165；Found:658.2169.
本实施例制备化合物3e:白色固体,熔点：176.1-177.8℃；产率87％；98％ee,>20:1dr,[α]D 20＝102.8(c 3.6,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.07min；τminor＝32.01min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.60(s,9H),2.11-2.16(m,1H),2.44(s,3H),2.71-2.75(m,1H),3.66-3.70(m,1H),4.09-4.15(m,1H),4.76-4.81(m,1H),5.78-5.81(m,1H),6.81(d,J＝8.5Hz,1H),6.90-6.92(m,2H),7.03-7.06(m,1H),7.19-7.24(m,2H),7.34-7.36(m,1H),7.44-7.48(m,1H),7.49-7.52(m,1H),7.86-7.88(m,1H)；13C NMR(CDCl3,125MHz)δ:11.6,28.0,29.7,31.7,43.3,51.1,80.3,84.8,115.0,117.9,120.5,122.1,124.7,127.0,128.3,129.0,129.1,132.8,134.0,136.1,138.7,148.3,155.7,160.1,171.3,176.2,192.0；HRMS(ESI-TOF)m/z:Calcd.for C35H30ClN3NaO8[M+Na]+:678.1619；Found:678.1619.
本实施例制备化合物3f:白色固体,熔点：176.2-177.4℃；产率90％；98％ee,>20:1dr,[α]D 20＝89.4(c 3.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.21min；τminor＝23.88min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.64(s,9H),2.20-2.25(m,1H),2.41(s,3H),2.68-2.73(m,1H),4.17-4.23(m,1H),4.54-4.57(m,1H),4.96-4.98(m,1H),5.77-5.79(m,1H),6.83(d,J＝8.5Hz,1H),6.92-6.94(m,2H),7.00-7.07(m,2H),7.12-7.20(m,2H),7.44-7.52(m,4H),7.87-7.89(m,1H)；13CNMR(CDCl3,125MHz)δ:11.6,26.9,28.1,29.7,32.3,43.2,51.0,80.2,84.7,114.3,117.9,120.6,122.0,123.7,124.2,126.8,127.0,127.9,128.1,129.0,129.3,129.6,132.6,134.2,136.1,138.3,148.5,155.5,160.2,171.3,176.7,192.1；HRMS(ESI-TOF)m/z:Calcd.for C35H30ClN3NaO8[M+Na]+:678.1619；Found:678.1615.
本实施例制备化合物3g:白色固体,熔点：190.0-191.2℃；产率88％；96％ee,>20:1dr,[α]D 20＝120.8(c 1.2,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝9.10min；τminor＝15.55min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.68(s,9H),2.21-2.27(m,1H),2.50(s,3H),2.72-2.76(m,1H),4.15-4.22(m,1H),4.55(d,J＝12.5Hz,1H),4.94-4.98(m,1H),5.78-5.80(m,1H),6.86(d,J＝8.5Hz,1H),7.00(d,J＝2.5Hz,1H),7.04-7.06(m,1H),7.08-7.11(m,1H),7.18-7.21(m,1H),7.24-7.27(m,1H),7.48-7.52(m,3H),7.56(d,J＝9.0Hz,1H),7.90-7.92(m,1H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.7,32.4,43.1,51.0,80.0,85.0,114.5,117.9,120.5,122.1,123.6,124.4,127.0,127.2,127.9,128.9,129.2,129.5,131.5,131.9,134.4,135.0,136.2,138.2,148.3,155.7,160.1,171.0,176.6,192.0；HRMS(ESI-TOF)m/z:Calcd.forC35H29Cl2N3NaO8[M+Na]+:712.1229；Found:712.1234.
本实施例制备化合物3h:白色固体,熔点：177.3-178.8℃；产率92％；96％ee,>20:1dr,[α]D 20＝87.7(c 4.8,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.30min；τminor＝38.12min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.62(s,9H),2.12-2.17(m,1H),2.44(s,3H),2.71-2.75(m,1H),3.65(d,J＝12.0Hz,1H),4.12-4.18(m,1H),4.78-4.83(m,1H),5.77-5.82(m,1H),6.81(d,J＝8.0Hz,1H),7.03-7.06(m,1H),7.12-7.14(m,1H),7.21-7.23(m,2H),7.34-7.37(m,1H),7.44-7.47(m,1H),7.54-7.56(m,1H),7.86-7.88(m,1H)；13C NMR(CDCl3,125MHz)δ:11.6,26.9,28.0,29.7,31.5,43.2,51.1,80.2,84.8,114.9,117.9,120.5,122.1,122.2,124.7,127.0,129.0,129.1,129.5,131.3,136.1,136.4,138.7,148.4,155.6,160.1,171.2,175.9,191.9；HRMS(ESI-TOF)m/z:Calcd.for C35H30BrN3NaO8[M+Na]+:722.1114；Found:722.1117.
本实施例制备化合物3i:白色固体,熔点：174.5-175.2℃；产率85％；97％ee,>20:1dr,[α]D 20＝95.8(c 3.6,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.93min；τminor＝23.87min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.64(s,9H),2.21-2.26(m,1H),2.42(s,3H),2.68-2.72(m,1H),4.18-4.24(m,1H),4.51(d,J＝12.5Hz,1H),4.98-4.50(m,1H),5.77-5.79(m,1H),6.83(d,J＝8.5Hz,1H),6.84-6.88(m,1H),7.04-7.08(m,2H),7.12-7.20(m,3H),7.44-7.52(m,3H),7.55-7.57(m,1H),7.87-7.89(m,1H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.7,32.3,43.3,51.2,80.0,84.8,114.3,117.9,120.6,122.1,124.1,124.2,125.4,127.1,127.4,128.0,128.1,129.1,129.6,131.9,133.2,134.4,136.1,138.3,148.5,155.6,160.3,171.3,176.8,192.2；HRMS(ESI-TOF)m/z:Calcd.for C35H30BrN3NaO8[M+Na]+:722.1114；Found:722.1114.
本实施例制备化合物3j:白色固体,熔点：179.2-180.5℃；产率84％；>99％ee,>20:1dr,[α]D 20＝67.6(c 3.0,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.68min；τminor＝55.26min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.60(s,9H),2.12-2.17(m,1H),2.44(s,3H),2.71-2.75(m,1H),3.68-3.72(m,1H),4.13-4.18(m,1H),4.78-4.83(m,1H),5.77-5.82(m,1H),6.69-6.72(m,1H),6.82(d,J＝8.5Hz,1H),6.90-6.92(m,1H),7.04-7.07(m,1H),7.20-7.23(m,2H),7.34-7.36(m,1H),7.45-7.48(m,1H),7.52-7.54(m,1H),7.86-7.88(m,1H)；13C NMR(CDCl3,125MHz)δ:11.6,26.9,28.0,29.7,31.5,43.3,51.0,80.2,84.8,114.9,115.2(d,JCF＝21.3Hz),117.9,120.5,122.1,122.2,124.7,127.0,129.1,129.6,136.2,136.7,138.8,148.4,155.6,160.1,162.0(d,JCF＝246.3Hz),171.3,176.1,192.0；HRMS(ESI-TOF)m/z:Calcd.forC35H30FN3NaO8[M+Na]+:662.1915；Found:662.1917.
本实施例制备化合物3k:白色固体,熔点：172.1-174.3℃；产率92％；92％ee,>20:1dr,[α]D 20＝71.5(c 3.2,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.69min；τminor＝18.94min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.60(s,9H),2.09(s,3H),2.11-2.14(m,1H),2.41(s,3H),2.69-2.73(m,1H),3.62-3.65(m,1H),4.11-4.17(m,1H),4.78-4.81(m,1H),5.78-5.82(m,1H),6.70-6.72(m,3H),6.80-6.83(m,2H),7.15-7.20(m,3H),7.32-7.35(m,1H),7.49-7.53(m,2H)；13C NMR(CDCl3,125MHz)δ:11.7,20.9,28.0,29.7,31.6,43.3,51.1,80.7,84.5,112.0(d,JCF＝23.8Hz),114.9,119.6,119.7,120.9,121.0,122.2,123.6(d,JCF＝23.8Hz),124.5,128.8,129.5,130.8,137.7,138.8,148.5,155.5,157.5(d,JCF＝241.3Hz),171.7,176.4,191.5；HRMS(ESI-TOF)m/z:Calcd.for C36H32FN3NaO8[M+Na]+:676.2071；Found:676.2075.
本实施例制备化合物3l:白色固体,熔点：175.6-177.1℃；产率92％；95％ee,>20:1dr,[α]D 20＝61.4(c 2.7,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.32min；τminor＝18.23min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ:1.56(s,9H),1.89(s,3H),2.09-2.15(m,1H),2.31(s,3H),2.61-2.66(m,1H),3.93-3.96(m,1H),4.14-4.21(m,1H),4.76-4.82(m,1H),5.70-5.75(m,1H),6.60(d,J＝7.2Hz,1H),6.73-6.76(m,1H),6.79-6.87(m,2H),7.04-7.13(m,3H),7.29-7.35(m,2H),7.42-7.47(m,2H)；13C NMR(CDCl3,100MHz)δ:11.6,19.6,28.1,29.7,31.7,43.4,51.0,80.7,84.6,112.0(d,JCF＝23.0Hz),114.7,119.6(d,JCF＝7.1Hz),121.0,122.5,123.5(d,JCF＝24.1Hz),124.0,125.9,126.2,127.9,128.9,129.1,130.5,132.9,136.1,138.7,148.5,155.6,156.3,157.6(d,JCF＝222.3Hz),171.7,177.0,191.6；HRMS(ESI-TOF)m/z:Calcd.for C36H32FN3NaO8[M+Na]+:676.2071；Found:676.2074.
本实施例制备化合物3m:白色固体,熔点：177.5-179.5℃；产率92％；92％ee,>20:1dr,[α]D 20＝46.8(c 4.0,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.22min；τminor＝17.19min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.60(s,9H),2.09-2.15(m,1H),2.44(s,3H),2.70-2.74(m,1H),3.66-3.70(m,1H),4.09-4.14(m,1H),4.77-4.79(m,1H),5.78-5.83(m,1H),6.80-6.83(m,2H),6.90-6.92(m,2H),7.17-7.24(m,3H),7.34-7.36(m,1H),7.49-7.52(m,2H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.7,31.6,43.3,51.1,80.6,84.9,112.1(d,JCF＝23.8Hz),115.1,119.7,121.0,122.2,123.7(d,JCF＝23.8Hz),124.8,128.4,129.1,129.2,132.7,134.1,138.8,148.3,155.7,156.4,157.6(d,JCF＝241.3Hz),171.2,176.2,191.3；HRMS(ESI-TOF)m/z:Calcd.for C35H29ClFN3NaO8[M+Na]+:696.1525；Found:696.1523.
本实施例制备化合物3n:白色固体,熔点：165.4-167.2℃；产率92％；93％ee,>20:1dr,[α]D 20＝106.4(c 2.5,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝12.03min；τminor＝20.86min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.64(s,9H),2.19-2.24(m,1H),2.41(s,3H),2.69-2.72(m,1H),4.17-4.22(m,1H),4.52-4.56(m,1H),4.93-4.98(m,1H),5.76-5.79(m,1H),6.81-6.84(m,1H),6.92-6.96(m,2H),7.00-7.04(m,1H),7.13-7.21(m,3H),7.47-7.54(m,4H)；13C NMR(CDCl3,125MHz)δ:11.6,28.1,29.7,32.2,43.2,51.0,80.2,84.8,112.0(d,JCF＝23.8Hz),114.3,119.6,119.7,121.0,123.6,123.7(d,JCF＝25.0Hz),124.3,126.8,127.8,128.0,129.1,129.4,129.7,132.5,134.2,138.3,148.5,155.6,156.4,157.5(d,JCF＝241.3Hz),171.1,176.7,191.4；HRMS(ESI-TOF)m/z:Calcd.for C35H29ClFN3NaO8[M+Na]+:696.1525；Found:696.1525.
本实施例制备化合物3o:白色固体,熔点：169.8-171.4℃；产率92％；91％ee,>20:1dr,[α]D 20＝74.3(c 4.3,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝12.80min；τminor＝20.68min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ:1.54(s,9H),2.02-2.09(m,1H),2.36(s,3H),2.63-2.68(m,1H),3.64-3.58(m,1H),4.03-4.10(m,1H),4.68-4.75(m,1H),5.68-5.74(m,1H),6.72-6.76(m,3H),7.05-7.16(m,5H),7.26-7.28(m,1H),7.42-7.48(m,2H)；13C NMR(CDCl3,100MHz)δ:11.6,27.9,28.0,29.7,31.4,43.2,51.0,80.4,84.8,112.0(d,JCF＝23.0Hz),115.0,119.6(d,JCF＝7.0Hz),120.9,121.0,121.2,123.6(d,JCF＝24.1Hz),124.7,128.9,129.2,129.6,131.4,136.3,138.7,148.4,155.7,157.5(d,JCF＝241.2Hz),171.0,175.9,191.2；HRMS(ESI-TOF)m/z:Calcd.for C35H29BrFN3NaO8[M+Na]+:740.1020；Found:740.1028.
本实施例制备化合物3p:白色固体,熔点：173.5-175.1℃；产率92％；90％ee,>20:1dr,[α]D 20＝134.0(c 1.3,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.10min；τminor＝20.33min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.56(s,9H),2.12-2.17(m,1H),2.33(s,3H),2.59-2.63(m,1H),4.10-4.14(m,1H),4.42-4.44(m,1H),4.90-4.92(m,1H),5.68-5.70(m,1H),6.72-6.79(m,2H),6.97-6.99(m,1H),7.03-7.11(m,4H),7.41-7.48(m,4H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.7,32.2,43.2,51.1,80.2,84.8,112.1(d,JCF＝23.8Hz),114.3,119.6,119.7,121.0(d,JCF＝7.5Hz),123.6(d,JCF＝23.6Hz),124.1,124.2,125.4,127.4,127.9,128.1,129.1,129.7,131.9,133.2,134.3,138.3,148.5,155.6,156.5,157.5(d,JCF＝242.5Hz),171.1,176.8,191.4；HRMS(ESI-TOF)m/z:Calcd.for C35H29BrFN3NaO8[M+Na]+:740.1014；Found:740.1011.
本实施例制备化合物3q:白色固体,熔点：177.3-179.1℃；产率92％；96％ee,>20:1dr,[α]D 20＝48.8(c 4.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.20min；τminor＝23.39min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ:1.53(s,9H),2.03-2.09(m,1H),2.35(s,3H),2.63-2.67(m,1H),3.59-3.63(m,1H),4.03-4.11(m,1H),4.69-4.75(m,1H),5.68-5.74(m,1H),6.61-6.65(m,2H),6.72-6.76(m,1H),6.82-6.84(m,1H),7.09-7.15(m,4H),7.26-7.28(m,1H),7.42-7.46(m,2H)；13C NMR(CDCl3,100MHz)δ:11.6,28.0,29.7,31.4,43.2,51.0,80.5,84.8,112.0(d,JCF＝24.2Hz),114.9,115.3(d,JCF＝21.0Hz),119.7(d,JCF＝8.0Hz),122.1,123.6(d,JCF＝24.4Hz),124.7,129.0(d,JCF＝12.0Hz),136.5(d,JCF＝7.2Hz),138.7,148.4,155.6,157.5(d,JCF＝236.7Hz),171.0,176.1,191.2；HRMS(ESI-TOF)m/z:Calcd.for C35H29F2N3NaO8[M+Na]+:680.1820；Found:680.1822.
本实施例制备化合物3r:白色固体,熔点：174.1-175.2℃；产率87％；90％ee,>20:1dr,[α]D 20＝83.3(c 2.4,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.62min；τminor＝22.85min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.63(s,9H),2.18-2.23(m,1H),2.31(s,3H),2.41(s,3H),2.68-2.72(m,1H),41.4-41.8(m,1H),4.52-4.57(m,1H),4.90-4.95(m,1H),5.76-5.81(m,1H),6.72(d,J＝8.5Hz,1H),6.92-6.94(m,2H),7.00-7.03(m,1H),7.12-7.20(m,2H),7.25-7.28(m,1H),7.48-7.52(m,3H),7.65-7.67(m,1H)；13C NMR(CDCl3,125MHz)δ:11.6,20.4,26.9,28.1,29.7,32.3,43.3,51.1,80.0,84.7,114.3,117.6,120.1,123.7,124.2,126.6,126.8,127.9,128.2,129.0,129.3,129.6,131.5,132.7,134.2,137.1,138.3,148.5,155.5,158.3,171.4,176.7,192.4；HRMS(ESI-TOF)m/z:Calcd.for C36H32ClN3NaO8[M+Na]+:692.1776；Found:692.1775.
本实施例制备化合物3s:白色固体,熔点：182.2-182.4℃；产率86％；91％ee,>20:1dr,[α]D 20＝72.5(c 3.6,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.90min；τminor＝25.97min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.64(s,9H),2.19-2.24(m,1H),2.31(s,3H),2.41(s,3H),2.67-2.71(m,1H),4.15-4.20(m,1H),4.49-4.52(m,1H),4.94-4.97(m,1H),5.76-5.78(m,1H),6.72(d,J＝8.5Hz,1H),6.84-6.87(m,1H),7.04-7.08(m,1H),7.11-7.20(m,3H),7.25-7.28(m,1H),7.48-7.52(m,2H),7.55-7.57(m,1H),7.66(s,1H)；13C NMR(CDCl3,125MHz)δ:11.7,20.5,28.1,29.7,32.4,43.3,51.2,79.8,84.8,114.3,117.7,120.2,124.1,124.2,125.4,126.6,127.4,128.1,129.0,129.6,131.5,133.2,134.4,137.2,138.3,148.6,155.6,158.4,171.4,176.8,192.4；HRMS(ESI-TOF)m/z:Calcd.for C36H32BrN3NaO8[M+Na]+:736.1270；Found:736.1275.
本实施例制备化合物3t:白色固体,熔点：158.1-159.6℃；产率82％；97％ee,>20:1dr,[α]D 20＝73.4(c 3.8,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.46min；τminor＝16.59min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),2.01-2.06(m,1H),2.33(s,3H),2.64-2.68(m,1H),3.55-3.58(m,1H),4.05-4.10(m,1H),4.73-4.75(m,1H),5.74-5.76(m,1H),6.73-7.03(m,9H),7.36-7.42(m,2H),7.80(d,J＝6.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:11.6,28.1,29.7,31.6,43.3,51.5,80.3,84.8,109.9(d,JCF＝23.8Hz),115.4(d,JCF＝22.5Hz),116.4,117.9,120.5,122.1,127.1,128.3,131.4,131.5,133.9,134.8,136.2,148.4,155.6,160.0(d,JCF＝242.5Hz),160.2,160.9,171.5,175.9,192.0；HRMS(ESI-TOF)m/z:Calcd.for C35H30FN3NaO8[M+Na]+:662.1909；Found:662.1915.
本实施例制备化合物3u:白色固体,熔点：150.3-152.1℃；产率86％；98％ee,>20:1dr,[α]D 20＝78.1(c 3.6,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.43min；τminor＝15.48min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),2.03(s,3H),2.34(s,3H),2.63-2.66(m,1H),3.53-3.55(m,1H),4.03-4.08(m,1H),4.72-4.74(m,1H),5.72-5.74(m,1H),6.66-6.83(m,6H),6.95-7.01(m,2H),7.36-7.44(m,2H),7.79(d,J＝6.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:11.6,20.9,28.0,29.7,31.6,43.3,51.5,80.0,84.7,109.8(d,JCF＝25.1Hz),115.3(d,JCF＝22.5Hz),116.4,117.9,120.5,122.0,127.0,128.9,130.7,131.6,134.8,136.1,137.9,148.5,155.5,159.9(d,JCF＝242.5Hz),160.2,171.7,175.9,192.0；HRMS(ESI-TOF)m/z:Calcd.forC36H32FN3NaO8[M+Na]+:676.2066；Found:676.2062.
本实施例制备化合物3v:白色固体,熔点：174.6-176.2℃；产率92％；96％ee,>20:1dr,[α]D 20＝89.7(c 2.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝38.49min；τminor＝19.54min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ:1.53(s,9H),1.98-2.05(m,1H),2.38(s,3H),2.64-2.69(m,1H),3.55-3.59(m,1H),4.03-4.06(m,1H),4.67-4.74(m,1H),5.69-5.75(m,1H),6.75(d,J＝8.4Hz,1H),6.83-6.88(m,4H),6.97-7.03(m,2H),7.37-7.47(m,2H),7.79-7.81(m,1H)；13C NMR(CDCl3,100MHz)δ:11.6,28.0,29.7,31.6,43.2,51.4,80.2,85.1,109.8(d,JCF＝24.7Hz),115.7(d,JCF＝22.4Hz),116.6,117.9,120.4,122.1,127.0,128.5,131.1(d,JCF＝8.1Hz),132.5,134.2,136.2,148.2,155.7,160.0(d,JCF＝244.3Hz),160.1,171.1,175.7,191.7；HRMS(ESI-TOF)m/z:Calcd.for C35H29ClFN3NaO8[M+Na]+:696.1525；Found:696.1521.
本实施例制备化合物3w:白色固体,熔点：148.5-149.9℃；产率87％；99％ee,>20:1dr,[α]D 20＝86.3(c 4.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(85/15 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝19.25min；τminor＝28.46min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),1.99-2.04(m,1H),2.38(s,3H),2.64-2.67(m,1H),3.55-3.57(m,1H),3.77(s,3H),4.02-4.04(m,1H),4.70-4.72(m,1H),5.72-5.74(m,1H),6.65-6.67(m,1H),6.74-6.76(m,1H),6.80-6.82(m,1H),6.86-6.88(m,2H),6.96-7.00(m,1H),7.19(s,2H),7.35-7.40(m,2H),7.80(d,J＝6.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:11.7,28.1,29.8,31.9,43.3,51.5,55.8,80.2,84.7,108.6,113.6,116.2,117.9,120.5,122.1,127.1,128.4,130.5,132.1,132.8,134.0,136.2,148.4,155.7,157.1,160.2,171.4,176.2,192.0；HRMS(ESI-TOF)m/z:Calcd.for C36H32ClN3NaO9[M+Na]+:708.1719；Found:708.1723.
本实施例制备化合物3x:白色固体,熔点：115.7-117.1℃；产率78％；96％ee,>20:1dr,[α]D 20＝47.1(c 2.1,MeOH)；The ee was determined by HPLC analysis using aChiralpak IA column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝9.79min；τminor＝20.29min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:-0.74--0.68(m,2H),-0.12--0.10(m,2H),0.64-0.65(m,1H),1.63-1.68(m,10H),1.80-1.90(m,1H),2.58-2.62(m,4H),3.80-3.86(m,1H),4.63-4.70(m,1H),5.46-5.52(m,1H),6.79(d,J＝10.5Hz,1H),6.83-6.86(m,1H),6.99-7.06(m,2H),7.41-7.45(m,1H),7.82-7.87(m,2H)；13C NMR(CDCl3,125MHz)δ:2.3,3.1,10.7,11.8,28.1,32.0,42.8,50.7,51.2,79.9,85.1,109.8(d,JCF＝23.8Hz),115.4(d,JCF＝22.5Hz),116.5,116.6,117.9,120.5,122.0,127.0,133.3,135.6,136.2,149.0,155.9,160.0(d,JCF＝242.5Hz),160.3,173.0,175.6,191.9；HRMS(ESI-TOF)m/z:Calcd.for C32H30FN3NaO8[M+Na]+:626.1909；Found:626.1915.
本发明的式(1)化合物具有重要的生物活性，体外对人白血病细胞(K562)肿瘤细胞的细胞毒性试验表明：此类式(1)所示结构的山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物对肿瘤细胞生长具有抑制作用，有可能发展成为新的防治肿瘤药物。但需强调的是本发明的化合物不限于人白血病细胞(K562)表示的细胞毒性。
药理实施例：化合物3e,3n,3t和3v对K562细胞的细胞毒性
K562(人慢性髓系白血病细胞)用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。细胞经过24小时的孵育后，分别将新配的化合物3e,3n,3t和3v的二甲基亚砜溶液以浓度梯度加入到各孔中，使孔中化合物最终浓度分别为5μmol/L,10μmol/L,20μmol/L,40μmol/L和80μmol/L。48小时后，每孔加入10μL MTT(5mg/mL)的磷酸盐缓冲液，再继续在37℃培养4小时后，离心5分钟除去未转化的MTT，每孔中加入150μL二甲基亚砜。以溶解还原的MTT晶体甲臜(formazan)，用酶标仪在490nm波长测定OD值。其中化合物3e,3n,3t和3v对K562细胞半抑制浓度IC50由spss软件(19版本)分析得到。化合物3e对K562肿瘤细胞的IC50为37.9μmol/L；化合物3n对K562肿瘤细胞的IC50为42.3μmol/L；化合物3t对K562肿瘤细胞的IC50为31.8μmol/L；化合物3v对K562肿瘤细胞的IC50为50.1μmol/L；而阳性对照顺铂对K562肿瘤细胞的IC50为23.5μmol/L。
实验结论：K562细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物对K562细胞具有较强的细胞毒性，有可能发展成新的具有抗肿瘤作用的药物，值得继续深入研究下去。

Claims (3)

1.一种山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物，其特征在于：该化合物具有如通式(Ⅰ)所示的结构：
Figure FDA0003529472430000011
式中，R1为甲氧基、氟或氢；R2为甲基、氟或氢；R3为甲基取代的苯基、卤素取代的苯基、苯基或环丙基。
2.一种如权利要求1所述的山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物的制备方法，其特征在于：其合成路线如下：
Figure FDA0003529472430000012
式中，R1为甲氧基、氟或氢；R2为甲基、氟或氢；R3为甲基取代的苯基、卤素取代的苯基、苯基或环丙基。
3.一种如权利要求1所述的山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物在制备防治白血病药物中的应用。
CN201910150938.4A 2019-02-28 2019-02-28 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用 Active CN110092793B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910150938.4A CN110092793B (zh) 2019-02-28 2019-02-28 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910150938.4A CN110092793B (zh) 2019-02-28 2019-02-28 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用

Publications (2)

Publication Number Publication Date
CN110092793A CN110092793A (zh) 2019-08-06
CN110092793B true CN110092793B (zh) 2022-04-29

Family

ID=67443839

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910150938.4A Active CN110092793B (zh) 2019-02-28 2019-02-28 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用

Country Status (1)

Country Link
CN (1) CN110092793B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110372714B (zh) * 2019-08-12 2022-03-15 贵州大学 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用
CN110684032B (zh) * 2019-08-13 2022-05-24 贵州大学 山酮素异恶唑骨架拼接吡唑啉酮或苯并呋喃酮类化合物及其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383030A (zh) * 2017-04-10 2017-11-24 贵州大学 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383030A (zh) * 2017-04-10 2017-11-24 贵州大学 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An expedient approach for the synthesis of dispiropyrrolidine bisoxindoles,spiropyrrolidine oxindoles and spiroindane-1,3-diones through 1,3-dipolar cycloaddition reactions;Neelakandan Vidhya Lakshmi;《Tetrahedron Letters》;20091221;第51卷;1064-1068页 *
通过1，3－偶极环加成反应合成3 － 吡咯螺环氧化吲哚的研究进展;周英;《山地农业生物学报》;20151231;第34卷(第2期);009-013页 *

Also Published As

Publication number Publication date
CN110092793A (zh) 2019-08-06

Similar Documents

Publication Publication Date Title
EA019040B1 (ru) Новый способ получения производных аминокислот
CN111875612B (zh) 色满酮拼接吡咯螺环氧化吲哚骨架与三氟甲基类化合物及其制备方法及应用
CN110092793B (zh) 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用
CN112390804B (zh) 环戊烷并色满酮拼接螺环氧化吲哚类化合物及其制备方法及应用
CN101772475B (zh) 拆分佐匹克隆的方法和中间化合物
CN109705130B (zh) 二氢色原酮骨架拼接多环吡咯螺环氧化吲哚化合物及其制备方法及应用
CN109776556B (zh) 吡唑啉酮山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
CN110156796B (zh) 异恶唑拼接3,3’-硫代吡咯啉酮双螺环氧化吲哚化合物及其制备方法及应用
CN109970753B (zh) 山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
CN109776554B (zh) 二氢色原酮拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
CN110372714B (zh) 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用
CN113444101B (zh) 环戊环并色满酮拼接双螺环茚二酮氧化吲哚类化合物及其制备方法及应用
CN110684032B (zh) 山酮素异恶唑骨架拼接吡唑啉酮或苯并呋喃酮类化合物及其制备方法及应用
CN110028519B (zh) 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用
CN111808113B (zh) 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用
US11840519B2 (en) Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process
JP3714964B2 (ja) 光学活性アミン類の製造方法
CN109776555B (zh) 山酮素骨架拼接异噁唑与双螺环氧化吲哚衍生物及其制备方法及应用
CN108947995B (zh) 一种多取代噁二嗪衍生物的制备方法
CN111793017A (zh) 一种内酰胺化合物的制备方法
CN111303209A (zh) 一种丙酚替诺福韦降解杂质的制备方法
CN113307815B (zh) 三氟甲基拼接双螺环色满酮骨架吡咯氧化吲哚类化合物及其制备方法及应用
CN114890975B (zh) 一种并环色满结构化合物及制备方法
Mereyala et al. Resolution of 1-arylalkylamines with 3-O-hydrogen phthalate glucofuranose derivatives: role of steric bulk in a family of resolving agents
KR0173861B1 (ko) N-치환된 티오카바모일기를 포함하는 신규한 카바메이트 화합물과 이의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant